Could the US election outcome and hopes of an imminent Covid-19 vaccine keep markets trending upwards?

  • While the battle for the US Senate is still undecided, the likely election outcome of a Democratic president and divided Congress appears favorable for equity markets.
  • Markets have been buoyed by this week’s announcement concerning the efficacy of a new Covid-19 vaccine, with those industries that have suffered the most under the virus restrictions proving to be notable beneficiaries of an improving outlook.
  • With large-scale monetary accommodation remaining in place, there appears to be a strong likelihood that the upward trend in markets will resume, with the very real possibility of a ‘melt-up’ into the end of the year and beyond.


The naming of Joe Biden as US president-elect over the weekend brought to an end the period of election-induced uncertainty, albeit with the promise of legal challenges from the Trump administration. Perhaps the most important US election issue that remains for investors, however, is the continuing battle for the Senate. While the Republican Party is predicted to remain in control of the upper chamber, with the results of four seats still outstanding this is by no means certain. In particular, additional ‘run-off’ votes will have to be held for two key Senate races in Georgia in early January as no candidate reached 50% of the vote.

Assuming the Republicans ultimately prevail in the Senate battle, this will prevent a Democratic ‘clean sweep’, giving the Republicans greater scope to limit the Biden administration. This calls into question whether the Democratic administration will be able to implement the policies outlined ahead of the election that formed a ‘Green New Deal’. A Republican Senate would also limit the ability of the new administration to implement new business regulation, in particular aggressive new rules for ‘big tech’ firms.

At the same time, as Democrats and Republicans have already indicated a willingness to work together to provide further fiscal support for the economy, there is the prospect of progress on the fiscal-aid front, but the untethered fiscal deficits and government spending that might have come about under a ‘blue clean sweep’ scenario now appear unlikely.

Such an outcome, with a divided Congress, has widely been perceived as optimal for the equity market – in effect a continuation of the status quo. And initially, in the wake of the election, markets pivoted back to the ‘everything duration’ Goldilocks momentum trade, favoring secular growth stocks over cyclical value – a positioning which has been dominant for more than five years. Many were therefore beginning to question whether the narrative had changed at all.

It’s the Economy, Stupid

Certainly, a Democratic clean sweep would have amounted to the clearest pathway to a regime change with respect to policy, i.e. the naked unification of monetary and fiscal policy. Without Biden ramping up the US fiscal deficit to finance government largesse, so the argument goes, cyclical equities would be unable to outperform, and hence support for secular growth areas would be maintained.

But while it is true that, with a Democratic clean sweep, larger US fiscal deficits financed by the Federal Reserve (Fed) – explicitly or tacitly – would be likely to lead to an environment more conducive for cyclical relative outperformance, some cyclical parts of the market have been holding their own for much of this year. Since the second quarter, the absolute and relative performance of many cyclically geared equities has reflected a continuing cyclical recovery, in contrast to the near-continuous hand-wringing about the economy. Of course, there has been a considerable dispersion of performance among cyclical sectors and industries. Many have lagged owing to the restrictions put in place to combat Covid-19 – hospitality-related businesses and energy being the obvious examples. But there has been a recovery of sorts nonetheless.

Enter the Vaccine

On Monday, markets were diverted from digesting the US election fallout when it was announced that a Covid-19 vaccine has been found to be more than 90% effective, and could be available for use by the end of the year, subject to regulatory approval. This potentially game-changing development was followed by a sharp rotation into more cyclical areas, as the outlook for those industries that have suffered the most under the virus restrictions appeared to materially improve.

The market dynamic is a repeat of the action seen in late May/early June when an unforeseen push to reopen economies prompted a sharp rotation, albeit on that occasion cut short by an acceleration of the virus in the south of the US. This time, the vaccine news makes it likely that the rotation can be stronger and more durable. Clearly the northern hemisphere winter will still be difficult as a vaccine is unlikely to be distributed in time to see a rolling back of restrictions in Europe and an avoidance of further restrictions in the US. Nevertheless, with a vaccine on the horizon, markets appear likely to look beyond the near term.

Bond Yields

The same drivers are likely to be evident in bond markets. Since the second quarter, other major markets ­– equities, credit, commodities and currencies – have all endorsed a cyclical recovery, but government bond markets have not, with yields remaining at close-to-historic lows. Covid-19, and in particular the response of governments, which has curtailed a recovery in activity, has been a substantial headwind to a move higher in yields. However, the vaccine announcements now clear the path for yields to rise.

Implications for Monetary and Fiscal Policy

One of the potential conclusions to draw from the vaccine development is that less monetary and fiscal support may now be required, and the shellacking of gold and silver this week is perhaps an indication of how the market is grappling with this. Without considering precise timeframes, a reduction in support appears likely: monetary and fiscal policy have been used to offset lost incomes for the private sector, and a broader recovery in this area will reduce the need for monetary and fiscal support.

However, there are still many unknowns around the timing of a potential vaccine. While the equity market will probably continue looking ahead to possible earnings implications of a broader lifting of restrictions, monetary and fiscal policy is likely to remain in place while economies continue to recover. The Fed has recently made it clear that it is ready to increase the size and duration of its quantitative-easing program in an anticipated economic slowdown, should Covid-19 restrictions be ramped up and fiscal stimulus be further delayed. With market expectations of inflation below the September highs and well below the Fed’s now-moving inflation target, the Fed has little reason to tighten monetary policy, so it appears unlikely that the central bank is ready to change direction at this juncture.

Case for a Melt-Up?

With large-scale monetary accommodation remaining in place, rising hopes for a Covid-19 vaccine, and a US election outcome that appears relatively benign for investors, there appears to be a strong likelihood that the upward trend in markets will resume, with the very real possibility of a ‘melt-up’ into the end of the year and beyond. While Covid-19 continues to cloud the outlook, its impact should continue to decline, and investors can begin to look forward to some economic normalization. But with the pandemic likely to have catalyzed lasting changes to the fabric of economies, we believe an active and disciplined approach will be as important as ever in seeking to identify the risks and potential rewards that lie ahead.

Authors

Brendan Mulhern

Brendan Mulhern

Global strategist, Real Return team

Any reference to a specific security, country or sector should not be construed as a recommendation to buy or sell this security, country or sector. Please note that strategy holdings and positioning are subject to change without notice.

Important information

This is a financial promotion. Issued by Newton Investment Management Limited, The Bank of New York Mellon Centre, 160 Queen Victoria Street, London, EC4V 4LA. Newton Investment Management Limited is authorized and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN and is a subsidiary of The Bank of New York Mellon Corporation. 'Newton' and/or 'Newton Investment Management' brand refers to Newton Investment Management Limited. Newton is registered in England No. 01371973. VAT registration number GB: 577 7181 95. Newton is registered with the SEC as an investment adviser under the Investment Advisers Act of 1940. Newton's investment business is described in Form ADV, Part 1 and 2, which can be obtained from the SEC.gov website or obtained upon request. Material in this publication is for general information only. The opinions expressed in this document are those of Newton and should not be construed as investment advice or recommendations for any purchase or sale of any specific security or commodity. Certain information contained herein is based on outside sources believed to be reliable, but its accuracy is not guaranteed. You should consult your advisor to determine whether any particular investment strategy is appropriate. This material is for institutional investors only.

Personnel of certain of our BNY Mellon affiliates may act as: (i) registered representatives of BNY Mellon Securities Corporation (in its capacity as a registered broker-dealer) to offer securities, (ii) officers of the Bank of New York Mellon (a New York chartered bank) to offer bank-maintained collective investment funds, and (iii) Associated Persons of BNY Mellon Securities Corporation (in its capacity as a registered investment adviser) to offer separately managed accounts managed by BNY Mellon Investment Management firms, including Newton and (iv) representatives of Newton Americas, a Division of BNY Mellon Securities Corporation, U.S. Distributor of Newton Investment Management Limited.

Unless you are notified to the contrary, the products and services mentioned are not insured by the FDIC (or by any governmental entity) and are not guaranteed by or obligations of The Bank of New York or any of its affiliates. The Bank of New York assumes no responsibility for the accuracy or completeness of the above data and disclaims all expressed or implied warranties in connection therewith. © 2020 The Bank of New York Company, Inc. All rights reserved.

Explore topics